# To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Difficile) Involvement in the Pathogenesis

> **NCT01533844** · — · TERMINATED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 1 (actual)

## Conditions studied

- Clostridium Difficile

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01533844
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2012-03
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Terminated due to the fact that the required number of trial subjects was not met.
- **Last updated:** 2015-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01533844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01533844, "To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Difficile) Involvement in the Pathogenesis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01533844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*